Form 4: Inhibrx Biosciences CEO Mark Lappe Increases Stake in Company

Inhibrx Biosciences CEO Mark Lappe has increased his indirect holdings in the company through purchases made by the Lappe Family Trust.

Summary

• Mark Lappe, the CEO of Inhibrx Biosciences, has reported changes in his beneficial ownership of the company's stock.
• On September 12, 2024, the Lappe Family Trust purchased 26,963 shares of common stock at a weighted average price of $15.05.
• On September 16, 2024, the Lappe Family Trust purchased an additional 13,037 shares of common stock at a weighted average price of $17.13.
• Following these transactions, Lappe's indirect beneficial ownership through the Lappe Family Trust increased to 705,548 shares.
• Lappe also indirectly owns 165,000 shares through the Lappe Descendants' Trust and 54,865 shares through The Mark Paul Lappe Roth IRA.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The CEO increasing their stake in the company is generally a positive sign, but it's a routine transaction and doesn't necessarily indicate a major shift in the company's prospects.

Positives

• The CEO's increased investment in the company may signal confidence in its future prospects.

Industry Context

Form 4 filings are standard practice and provide transparency into the trading activities of company insiders. These filings are closely watched by investors as they can provide insights into management's perspective on the company's valuation and future performance.

Stakeholder Impact

• Shareholders may view the CEO's increased investment as a positive signal.

Key Dates